BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34904905)

  • 1. Classification of early-stage colon cancer with Immunoscore
    Yalcin S; Philip PA; Athanasiadis I; Bazarbashi S; Shamseddine A
    Future Oncol; 2022 Feb; 18(5):613-623. PubMed ID: 34904905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
    Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
    Ascierto PA; Marincola FM; Fox BA; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoscore
    Blair HA
    Mol Diagn Ther; 2020 Jun; 24(3):365-370. PubMed ID: 32232741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions.
    Pagès F; Taieb J; Laurent-Puig P; Galon J
    Oncoimmunology; 2020 Aug; 9(1):1812221. PubMed ID: 32939329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of risk assessment in colon cancer: immunity is key.
    Hijazi A; Galon J
    Oncoimmunology; 2024; 13(1):2347441. PubMed ID: 38694625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
    Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoscore and its introduction in clinical practice.
    Galon J; Lanzi A
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):152-161. PubMed ID: 32107902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.
    Lanzi A; Sinicrope FA; Benson AB; Galon J
    Oncoimmunology; 2020 Jul; 9(1):1796003. PubMed ID: 32934890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness and robustness of Immunoscore for personalized management of cancer patients.
    Marliot F; Pagès F; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1832324. PubMed ID: 33194318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of prognostic factors after radical resection in 628 patients with stage II or III colon cancer].
    Qin Q; Yang L; Zhou AP; Sun YK; Song Y; DU F; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):212-6. PubMed ID: 23880003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.
    Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Vliet SVL; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into Adjuvant Therapy for Localized Colon Cancer.
    González NS; Ros Montaña FJ; Illescas DG; Argota IB; Ballabrera FS; Élez Fernández ME
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):507-520. PubMed ID: 35577707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey.
    Kasi A; Dotan E; Poage GM; Catteau A; Vernerey D; George M; Barzi A
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer.
    Marliot F; Chen X; Kirilovsky A; Sbarrato T; El Sissy C; Batista L; Van den Eynde M; Haicheur-Adjouri N; Anitei MG; Musina AM; Scripcariu V; Lagorce-Pagès C; Hermitte F; Galon J; Fieschi J; Pagès F
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
    Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.